Header Logo

Connection

Erica Erlank to Sirolimus

Back to Details
This is a "connection" page, showing publications Erica Erlank has written about Sirolimus.
Erica Erlank
Connection Strength
0,051
Sirolimus
  1. The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages. Sci Transl Med. 2022 10 19; 14(667):eabo7219.
    View in: PubMed
    Score: 0,051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.